Fig. 6.

C7 inhibits proliferation of KRAS-mutant cells with increased efficacy when combined with MAPK or PI3K inhibitors. (A) BxPC-3, MiaPaCa-2, PANC-1, and MOH cells were seeded in 96-well plates. After 24 h, fresh growth medium was added supplemented with 1% DMSO and 1/4 or 1/2 of the calculated IC50 of each indicated drug as single or combination treatment. Cells were counted 72 h later (mean ± SEM, n = 3) (*P < 0.05 and **P < 0.01). (B) The CI of each combination treatment was calculated using the Chou–Talalay method (CI = 1, antagonistic; CI < 1, synergistic; and CI > 1, additive).